Drug Approval
Name: Briumvi
Active Ingredient: ublituximab-xiiy
Indications: To treat relapsing forms of multiple sclerosis
Approval Date: 12/28/2022
Company: TG Therapeutics, Inc.
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf